Viking Global Investors’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $399M | Buy |
7,062,077
+1,025,141
| +17% | +$59.8M | 1.12% | 36 |
|
|
2025
Q4 | $359M | Sell |
6,036,936
-2,285,243
| -27% | -$124M | 0.95% | 42 |
|
|
2025
Q3 | $451M | Sell |
8,322,179
-3,966,432
| -32% | -$227M | 1.17% | 37 |
|
|
2025
Q2 | $676M | Buy |
12,288,611
+1,488,552
| +14% | +$87.7M | 1.95% | 14 |
|
|
2025
Q1 | $763M | Buy |
10,800,059
+289,509
| +3% | +$19.5M | 2.43% | 11 |
|
|
2024
Q4 | $691M | Buy |
10,510,550
+757,257
| +8% | +$50.7M | 2.24% | 16 |
|
|
2024
Q3 | $686M | Buy |
9,753,293
+2,689,729
| +38% | +$225M | 2.5% | 15 |
|
|
2024
Q2 | $582M | Buy |
7,063,564
+647,276
| +10% | +$53.9M | 2.24% | 18 |
|
|
2024
Q1 | $560M | Buy |
6,416,288
+1,526,834
| +31% | +$137M | 2.09% | 19 |
|
|
2023
Q4 | $471M | Buy |
4,889,454
+673,998
| +16% | +$59.6M | 1.73% | 20 |
|
|
2023
Q3 | $373M | Buy |
4,215,456
+58,671
| +1% | +$5.22M | 1.51% | 24 |
|
|
2023
Q2 | $360M | Buy |
4,156,785
+1,988,168
| +92% | +$187M | 1.48% | 26 |
|
|
2023
Q1 | $211M | Sell |
2,168,617
-3,105,003
| -59% | -$322M | 0.99% | 31 |
|
|
2022
Q4 | $546M | Buy |
5,273,620
+174,456
| +3% | +$16.4M | 2.73% | 13 |
|
|
2022
Q3 | $432M | Buy |
5,099,164
+46,571
| +0.9% | +$4.15M | 2% | 20 |
|
|
2022
Q2 | $419M | Buy |
5,052,593
+1,300,200
| +35% | +$104M | 1.92% | 24 |
|
|
2022
Q1 | $289M | Buy |
3,752,393
+882,446
| +31% | +$73.8M | 1.17% | 26 |
|
|
2021
Q4 | $254M | Buy |
+2,869,947
| New | +$237M | 0.73% | 41 |
|
|
2020
Q2 | – | Sell |
-1,453,625
| Closed | -$123M | – | 75 |
|
|
2020
Q1 | $123M | Sell |
1,453,625
-168,114
| -10% | -$14.5M | 0.64% | 40 |
|
|
2019
Q4 | $137M | Sell |
1,621,739
-1,436,365
| -47% | -$108M | 0.64% | 37 |
|
|
2019
Q3 | $206M | Buy |
3,058,104
+467,753
| +18% | +$36M | 1.07% | 26 |
|
|
2019
Q2 | $222M | Sell |
2,590,351
-2,538,558
| -49% | -$217M | 1% | 26 |
|
|
2019
Q1 | $456M | Buy |
5,128,909
+37,272
| +0.7% | +$3.45M | 2.61% | 12 |
|
|
2018
Q4 | $434M | Buy |
5,091,637
+962,696
| +23% | +$91.6M | 2.47% | 14 |
|
|
2018
Q3 | $400M | Buy |
4,128,941
+869,184
| +27% | +$86.8M | 2.22% | 13 |
|
|
2018
Q2 | $307M | Buy |
3,259,757
+1,577,291
| +94% | +$138M | 1.76% | 18 |
|
|
2018
Q1 | $136M | Buy |
+1,682,466
| New | +$144M | 0.82% | 30 |
|
|
2017
Q3 | – | Sell |
-259,656
| Closed | -$23.6M | – | 62 |
|
|
2017
Q2 | $23.6M | Sell |
259,656
-616,457
| -70% | -$56.1M | 0.16% | 52 |
|
|
2017
Q1 | $76.9M | Sell |
876,113
-522,344
| -37% | -$46.5M | 0.34% | 44 |
|
|
2016
Q4 | $116M | Buy |
1,398,457
+908,153
| +185% | +$78.1M | 0.53% | 36 |
|
|
2016
Q3 | $45.4M | Buy |
+490,304
| New | +$46.2M | 0.2% | 51 |
|
|
2016
Q2 | – | Sell |
-602,116
| Closed | -$49.7M | – | 56 |
|
|
2016
Q1 | $49.7M | Buy |
+602,116
| New | +$49M | 0.22% | 49 |
|
Other funds holding BMRN
VCM
VPM
Viking Global Investors's BMRN Position: Q1 2026 in Review
Viking Global Investors increased its BioMarin Pharmaceuticals (BMRN) stake by 17% in Q1 2026, buying an estimated $59.8M and bringing the position to 7,062,077 shares worth $399M. The position accounts for 1.12% of the portfolio, ranked #36.
Viking Global Investors first reported a position in BMRN in Q1 2016 and has held it in 32 quarters since. The position peaked at $763M in Q1 2025. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.
- Viking Global Investors held 7,062,077 shares of BioMarin Pharmaceuticals worth $399M as of Q1 2026.
- Viking Global Investors bought 1,025,141 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $59.8M.
- BioMarin Pharmaceuticals made up 1.12% of Viking Global Investors's portfolio in Q1 2026, its #36 holding.
- Viking Global Investors first reported a position in BioMarin Pharmaceuticals in Q1 2016 and has held it in 32 quarters since.
- Viking Global Investors's BioMarin Pharmaceuticals position peaked at $763M in Q1 2025.
- 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.
Based on Viking Global Investors's 13F filing for Q1 2026, filed 15 May 2026.